CDC-RFA-DD21-2103: Improving the Health of People with Mobility Limitations and Intellectual/Developmental Disabilities through State-based Public Health Programs
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCBDDD notices from 2021.
Centers for Disease Control - NCBDDD offered grants of up to $585,000 (at least $572,500) to any type of organization. It expected to make about 10 awards worth $28.6 million in total. Applications closed on May 11, 2021.
From the official notice on Grants.gov, last changed April 27, 2021. Checked November 7, 2026.
- Award ceiling$585,000
- Award floor$572,500
- Total funding$28.6 million
- Expected awards10
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 12, 2021 |
|---|---|
| Deadline | May 11, 2021 |
| Archived by Grants.gov | June 10, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
The award ceiling for this NOFO is $585,000. CDC will consider any application requesting an award higher than $585,000 as non-responsive and will not review it further.
Is this a realistic fit?
- Past Disabilities Prevention awards averaged $1.2 million; this notice allows up to $585,000 per award.
- Most of the program's money (38% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) supports a new five-year, non-research cooperative agreement to address statewide or jurisdictional needs related to reducing health disparities among adults with intellectual and developmental disabilities (IDD), and adults with mobility limitations (ML) in the United States. In support of the overarching goal of reducing health disparities among adults with IDD and adults with ML, this NOFO will provide funding to agencies, organizations, and institutions within states and jurisdictions to: 1) establish, expand, and enhance partnerships with organizations that serve adults with IDD and adults with ML; 2) conduct a needs assessment of communities within states and jurisdictions to identify gaps in resources and tools to reduce health disparities among adults with IDD and adults with ML, and identify action steps to fill those gaps; 3) provide training on accessible preventive health care for adults with IDD and adults with ML to healthcare providers within states and jurisdictions; 4) implement and evaluate a demonstration project to link adults with IDD to preventive health care and health promotion programs in their community; 5) implement evidence-based health promotion interventions, as well as policy, system and environmental (PSE) changes, and develop resources and tools to address health disparities among adults with IDD and adults with ML; and 6) disseminate key findings and lessons learned. The projected long-term outcomes of this NOFO among adults with IDD and adults with ML include:1) improved access to recommended preventive health care and other health services; 2) reduced unmet healthcare needs for mental health conditions, (e.g., depression and anxiety) and their risk factors; 3) increased healthy lifestyle behaviors and physical, mental, and emotional wellness; and 4) reduced prevalence of chronic conditions, (e.g., diabetes) and their risk factors.
Who has won Disabilities Prevention grants before
From fiscal 2021 to 2025, Disabilities Prevention (93.184) awarded $200 million across 169 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Special Olympics Inc. | District of Columbia | 1 | $47.3 million |
| University of Alabama at Birmingham | Alabama | 3 | $18.1 million |
| The Johns Hopkins University | Maryland | 3 | $6.9 million |
| American Academy of Pediatrics | Illinois | 2 | $6.3 million |
| Massachusetts Department of Public Health | Massachusetts | 4 | $5.3 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DD21-2103 still open?
No. It closed on May 11, 2021.
Who can apply for Improving the Health of People with Mobility Limitations and Intellectual/Developmental Disabilities through State-based Public Health Programs?
Centers for Disease Control - NCBDDD accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Improving the Health of People with Mobility Limitations and Intellectual/Developmental Disabilities through State-based Public Health Programs?
Closed May 11, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $585,000 each. About $28.6 million in total across about 10 awards.
Who has won Disabilities Prevention grants before?
The largest recipients over five fiscal years were Special Olympics Inc., University of Alabama at Birmingham, The Johns Hopkins University. The program made 169 awards worth $200 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)